Blockade of PD-1 effectively inhibits in vivo malignant transformation of oral mucosa

References

• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-489. doi:10.1038/nature10673. PMID:22193102
   PubMed Web of Science ®Google Scholar
• Balar AV, Weber JS. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother. 2017;66(5):551-564. doi:10.1007/s00262-017-1954-6. PMID:28213726
   PubMed Web of Science ®Google Scholar
• Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682-687. doi:10.1038/nature04444. PMID:16382236
   PubMed Web of Science ®Google Scholar
• Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4:127r-137r. doi:10.1126/scitranslmed.3003689.
   Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-2465. doi:10.1056/NEJMoa1200694. PMID:22658128
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134-144. doi:10.1056/NEJMoa1305133. PMID:23724846
   PubMed Web of Science ®Google Scholar
• Bagley SJ, Bauml JM, Langer CJ. PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer. Clin Adv Hematol Oncol. 2015;13:676-683 PMID:27058572
   PubMed Web of Science ®Google Scholar
• Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, Brunelli M, Piva F, Berardi R, Montironi R, et al. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Cancer Treat Rev. 2015;41:114-121. doi:10.1016/j.ctrv.2014.12.013. PMID:25586601
   PubMed Web of Science ®Google Scholar
• Fuereder T. Immunotherapy for head and neck squamous cell carcinoma. Memo. 2016;9:66-69. doi:10.1007/s12254-016-0270-8. PMID:27429658
   PubMedGoogle Scholar
• Kanojia D, Vaidya MM. 4-nitroquinoline-1-oxide induced experimental oral carcinogenesis. Oral Oncol. 2006;42:655-667. doi:10.1016/j.oraloncology.2005.10.013. PMID:16448841
   PubMed Web of Science ®Google Scholar
• Hawkins BL, Heniford BW, Ackermann DM, Leonberger M, Martinez SA, Hendler FJ. 4NQO carcinogenesis: a mouse model of oral cavity squamous cell carcinoma. Head Neck. 1994;16:424-432. doi:10.1002/hed.2880160506. PMID:7960739
   PubMed Web of Science ®Google Scholar
• Ide F, Oda H, Nakatsuru Y, Kusama K, Sakashita H, Tanaka K, Ishikawa T. Xeroderma pigmentosum group A gene action as a protection factor against 4-nitroquinoline 1-oxide-induced tongue carcinogenesis. Carcinogenesis. 2001;22:567-572. doi:10.1093/carcin/22.4.567. PMID:11285190
   PubMed Web of Science ®Google Scholar
• Ma G, Ikeda H, Inokuchi T, Sano K. Effect of photodynamic therapy using 5-aminolevulinic acid on 4-nitroquinoline-1-oxide-induced premalignant and malignant lesions of mouse tongue. Oral Oncol. 1999;35:120-124. doi:10.1016/S1368-8375(98)00066-9. PMID:10211320
   PubMed Web of Science ®Google Scholar
• Tang XH, Knudsen B, Bemis D, Tickoo S, Gudas LJ. Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice. Clin Cancer Res. 2004;10:301-313. doi:10.1158/1078-0432.CCR-0999-3. PMID:14734483
   PubMed Web of Science ®Google Scholar
• Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol. 2011;11:856-861. doi:10.1016/j.intimp.2011.01.030. PMID:21315783
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454. doi:10.1056/NEJMoa1200690. PMID:22658127
   PubMed Web of Science ®Google Scholar
• Supsavhad W, Dirksen WP, Martin CK, Rosol TJ. Animal models of head and neck squamous cell carcinoma. Vet J. 2016;210:7-16. doi:10.1016/j.tvjl.2015.11.006. PMID:26965084
   PubMed Web of Science ®Google Scholar
• Czerninski R, Amornphimoltham P, Patel V, Molinolo AA, Gutkind JS. Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prev Res (Phila). 2009;2:27-36. doi:10.1158/1940-6207.CAPR-08-0147. PMID:19139015
   PubMed Web of Science ®Google Scholar
• Li J, Liang F, Yu D, Qing H, Yang Y. Development of a 4-nitroquinoline-1-oxide model of lymph node metastasis in oral squamous cell carcinoma. Oral Oncol. 2013;49:299-305. doi:10.1016/j.oraloncology.2012.10.013. PMID:23187306
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang S, Gong D, Qin Y, Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol. 2010;7:389-395. doi:10.1038/cmi.2010.28. PMID:20514052
   PubMed Web of Science ®Google Scholar
• Malaspina TS, Gasparoto TH, Costa MR, de Melo EF, Jr, Ikoma MR, Damante JH, Cavassani KA, Garlet GP, da Silva JS, Campanelli AP. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. Cancer Immunol Immunother. 2011;60:965-974. doi:10.1007/s00262-011-1007-5. PMID:21442435
   PubMed Web of Science ®Google Scholar
• Waki K, Yamada T, Yoshiyama K, Terazaki Y, Sakamoto S, Matsueda S, Komatsu N, Sugawara S, Takamori S, Itoh K, et al.. PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer. Cancer Sci. 2014;105:1229-1235. doi:10.1111/cas.12502. PMID:25117757
   PubMed Web of Science ®Google Scholar
• Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443:350-354. doi:10.1038/nature05115. PMID:16921384
   PubMed Web of Science ®Google Scholar
• Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, Boulassel MR, Delwart E, Sepulveda H, Balderas RS, et al.. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. 2006;12:1198-1202. doi:10.1038/nm1482. PMID:16917489
   PubMed Web of Science ®Google Scholar
• Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, Bruno TC, Richmon JD, Wang H, Bishop JA, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73:1733-1741. doi:10.1158/0008-5472.CAN-12-2384. PMID:23288508
   PubMed Web of Science ®Google Scholar
• Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, Salomao D, Cheville J, Hirano F, Lin W, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003;63:6501-6505 PMID:14559843
   PubMed Web of Science ®Google Scholar
• Zandberg DP, Strome SE. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 2014;50:627-632. doi:10.1016/j.oraloncology.2014.04.003. PMID:24819861
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:123-135. doi:10.1056/NEJMoa1504627. PMID:26028407
   PubMed Web of Science ®Google Scholar
• Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54:307-314. doi:10.1007/s00262-004-0593-x. PMID:15599732
   PubMed Web of Science ®Google Scholar
• Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467-477. doi:10.1038/nri2326. PMID:18500231
   PubMed Web of Science ®Google Scholar
• Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, Yang YP, Tien P, Wang FS. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer. 2011;128:887-896. doi:10.1002/ijc.25397. PMID:20473887
   PubMed Web of Science ®Google Scholar
• Quan L, Chen X, Liu A, Zhang Y, Guo X, Yan S, Liu Y. PD-1 Blockade can restore functions of T-Cells in Epstein-Barr Virus-Positive Diffuse large B-cell lymphoma in vitro. PLoS One. 2015;10:e136476. doi:10.1371/journal.pone.0136476.
   PubMed Web of Science ®Google Scholar
• Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizée G, Radvanyi L, et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res. 2012;72:5209-5218. doi:10.1158/0008-5472.CAN-12-1187. PMID:22915761
   PubMed Web of Science ®Google Scholar
• John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19:5636-5646. doi:10.1158/1078-0432.CCR-13-0458. PMID:23873688
   PubMed Web of Science ®Google Scholar
• Mkrtichyan M, Chong N, Abu ER, Wallecha A, Singh R, Rothman J, Khleif SN. Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy. J Immunother Cancer. 2013;1:15. doi:10.1186/2051-1426-1-15. PMID:24829751
   PubMedGoogle Scholar
• Belai EB, de Oliveira CE, Gasparoto TH, Ramos RN, Torres SA, Garlet GP, Cavassani KA, Silva JS, Campanelli AP. PD-1 blockage delays murine squamous cell carcinoma development. Carcinogenesis. 2014;35:424-431. doi:10.1093/carcin/bgt305. PMID:24031027
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-571. doi:10.1038/nature13954. PMID:25428505
   PubMed Web of Science ®Google Scholar
• Yu GT, Bu LL, Huang CF, Zhang WF, Chen WJ, Gutkind JS, Kulkarni AB, Sun ZJ. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPalpha axis in HPV negative head and neck squamous cell carcinoma. Oncotarget. 2015;6:42067-42080. doi:10.18632/oncotarget.5955. PMID:26573233
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114:1537-1544. doi:10.1182/blood-2008-12-195792. PMID:19423728
   PubMed Web of Science ®Google Scholar
• Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010;207:2175-2186. doi:10.1084/jem.20100637. PMID:20819923
   PubMed Web of Science ®Google Scholar
• Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, Klemm M, Kuchroo VK, Freeman GJ, Sharpe AH. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A. 2004;101:10691-10696. doi:10.1073/pnas.0307252101. PMID:15249675
   PubMed Web of Science ®Google Scholar
• Wong RM, Scotland RR, Lau RL, Wang C, Korman AJ, Kast WM, Weber JS. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol. 2007;19:1223-1234. doi:10.1093/intimm/dxm091. PMID:17898045
   PubMed Web of Science ®Google Scholar
• Beury DW, Parker KH, Nyandjo M, Sinha P, Carter KA, Ostrand-Rosenberg S. Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. J Leukoc Biol. 2014;96:1109-1118. doi:10.1189/jlb.3A0414-210R. PMID:25170116
   PubMed Web of Science ®Google Scholar
• Lu C, Redd PS, Lee JR, Savage N, Liu K. The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells. Oncoimmunology. 2016;5:e1247135. doi:10.1080/2162402X.2016.1247135. PMID:28123883
   PubMed Web of Science ®Google Scholar
• Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211:781-790. doi:10.1084/jem.20131916. PMID:24778419
   PubMed Web of Science ®Google Scholar
• Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, Cho HI, Celis E, Quiceno DG, Padhya T, et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207:2439-2453. doi:10.1084/jem.20100587. PMID:20876310
   PubMed Web of Science ®Google Scholar
• Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol. 2009;182:5693-5701. doi:10.4049/jimmunol.0900092. PMID:19380816
   PubMed Web of Science ®Google Scholar
• Mougiakakos D, Johansson CC, Kiessling R. Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood. 2009;113:3542-3545. doi:10.1182/blood-2008-09-181040. PMID:19050306
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL, Schneck J, Gabrilovich DI. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13:828-835. doi:10.1038/nm1609. PMID:17603493
   PubMed Web of Science ®Google Scholar